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Purpose: To evaluate the effect of vitamin B-complex on the nephrotoxicity of gentamicin in 
an established rat model. 
Methods: Adult Swiss albino rats weighing 170±20g were divided into 4 groups of 4 rats 
each. Each group was given one of the following: placebo injection (Control), 80mg/kg of 
gentamicin sulphate alone or with 1.5ml/kg/3ml/kg body weight of vitamin B-complex 
(intramuscular) containing 10mg thiamine, 1.5mg riboflavin and 1.0mg pyridoxal-6-phosphate 
per ml.  
Results: In the Swiss albino rats, daily intramuscular 80mg/kg gentamicin sulphate 
significantly (p<0.05) and consistently produced biochemical signs of nephrotoxicity after 5 
days. Also, 1.5 ml/kg of B-complex significantly (p<0.05) ameliorated the rate and extent of 
increase in serum urea and creatine while 3ml/kg of the same drug completely prevented the 
increase in serum urea and creatine in this model. 
Conclusion: Vitamin B-complex dose-dependently ameliorated gentamicin-induced 
nephrotoxicity in adult Swiss albino rats when given intramuscularly. This finding may have 
important clinical utility.  
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Introduction 
 
Gentamicin is a bactericidal antibiotic with 
wide clinical use but disturbing toxicity. 
Nephrotoxicity and ototoxicity are the most 
common adverse reactions
1,2
 . While 
nephrotoxicity is almost always reversible due 
to the regenerating ability of the proximal renal 
tubules
1
, gentamicin still contributes to an 
increased incidence of the rather permanent 
ototoxicity
2
. Various attempts at controlling 
gentamicin toxicity have been frustrated by 
lack of a clear understanding of the 
mechanism of toxicity.  Nephrotoxicity has 
been related to a gentamycin trough 
concentration above 2µg/ml, calcium 
deficiency, calcium channel activation, 
prostaglandins pathways, free radical 
generation, pyridoxal phosphate deficiency 
and ascorbic acid depletion
1
. Once daily and 
extended interval dosing were designed to 
optimize the concentration-dependent 
antibiotic activity and essentially time-
dependent toxicity of gentamicin but the rather 
wide difference in serum concentrations and 
the fact that these dosing modes have not 
been substantiated in pregnancy, paediatric  
age group and endocarditis, indicate that 
there are still limitations using these 
approaches
3
. Though a recent study suggests 
some usefulness of the approach in neonates, 
trough levels were still above 2µg/ml even at 
q48 hours dosing
4
.  Other attempts at 
controlling gentamicin toxicity, including the 
use of pyridoxal phosphate, ascorbic acid, 







 have shown 
either promising or inconsistent results in 
animals . Those that showed limited efficacy 
have been difficult to apply clinically due to 
caution in administering agents that could be 
toxic themselves or require dose schedules 
that are not practical in patients
1
. Hence, an 
agent that is known to be clinically safe and 
effective as formulated would be easier to use 
clinically if found to be effective in ameliorating 
gentamicin toxicity. Vitamin B-complex could 
be such an agent. 
Vitamin B-complex is a well known pre-
formulated combination of water-soluble B1 
(thiamine), B2 (riboflavin) and B6 (pyridoxal) 
with or without nicotinamide and ascorbic 
acid. Depletion of some of these ingredients 
has been suggested to contribute to 
gentamicin toxicity
7,8,9
. This study was carried 
out as a preliminary evaluation of the 
influence of B-complex, administered 





Adult, female, Swiss albino rats, 
weighing170±20g, were obtained from the 
breeding unit of the Veterinary Research 
Institute, Vom, Nigeria, and randomly 
distributed into 4 groups of 4 rats each. The 
rats were housed in groups at a room 
temperature of 23 ± 3°C and relative humidity 
of 53-60%, 12 hours light and 12 hours 
darkness cycles, fed ad libitum on water and 
standard chow, and acclimatized for 14 days 
before experimentation. The groups were 
randomly scheduled to receive the following: 
Group 1: 0.9% saline (placebo) intramus-
cularly (i.m.) daily for 10 days; Group 2: 
gentamicin only 80mg/kg body weight/day i.m. 
for 10days; Group 3: gentamicin 80mg/kg 
body weight /day i.m. plus 1.5ml/kg body 
weight of vitamin B-complex daily for 10 days; 
and Group 4: gentamicin 80 mg /kg body 
weight /day i.m. plus 3 ml/kg of vitamin B-
complex daily for 10 days . B-complex 
(JINLIN-Pharmacy China, with National 
Agency for Food and Drug Administration and 
Control [NAFDAC] registration no. 04-7068) 
containing 10mg, 1.5 mg and 1.0 mg of B1, 
B2 and B6, respectively, per ml, and 
gentamicin sulphate injection (Gentalek
®
, Lek 
Pharmaceutical and Chemical Company, 
Veroskova, Slovenia with NAFDAC no. 04-
0220) were used for the study. The dose of 
gentamicin used has been consistently 
demonstrated to induce nephrotoxicity in adult 
rats
10
 while the dose of B-complex used was 
the pharmacological equivalent (in rats) of the 
usual clinical dose in man
11
. The animals were 
weighed every alternate day and the last 
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known weight was used for dose calculations.  
Blood samples were collected by tail bleeding 
at day zero (day 1 being the day treatment 
was started) and the other blood samples 
were collected by cardiac puncture 24 hours 
after the last administration. Each sample was 
collected in a sterile sample bottle without 
anticoagulant and the serum was removed for 
analysis. Serum creatine and urea were 
quantified using reagent kits from Bio-
Analytics Company (Palm City, U.S.A.). The 








software.  Student’s t-test was used for within 
group comparison while one-way ANOVA with 
Bonferroni error correction was used for 
between groups comparison. The animal 
experiment was carried out in accordance with 
the National Institutes of Health guidelines 
and was approved by the Animal Ethical 
Committee of the College of Health Sciences, 




In Swiss albino rats, daily doses of 
gentamicin, 80 mg i.m., significantly (p<0.05) 
and progressively increased serum creatine 
(1.33±0.22, 3.38±0.22, and 4.78±0.46 mmol/l 
at days 0, 5 and 10, respectively) and serum 
urea (6.95±2.07, 18.28±1.01, and 42.18±1.18 
mg/dl at days 0, 5 and 10, respectively) during 
the study when compared to placebo-treated 
animals (control) that revealed no significant 
difference in these parameters (Table 1). Also, 
1.5 ml/kg body weight of vitamin B-complex 
significantly (p<0.05) ameliorated the rate and 
extent of increase in serum creatine and urea 
while 3ml /kg body weight of vitamin B-
complex completely prevented an increase in 
serum urea and creatine throughout the 
duration of the study (Figures 1 and 2). There 
was a slight but insignificant (p>0.05) 
reduction in body weight in all groups by day 5 
of the experiment as shown in Table 1.  
    
Discussion 
 
This study shows that 80 mg/kg body 
weight/day of gentamicin sulphate (i.m.) 
consistently produced nephrotoxicity as 
reflected by the progressive increase in serum 
urea and creatine.  These consistent effects 
have been recognized
5,6,7
 and suggest that 
histological studies of the kidney may not be 
necessary to confirm nephrotoxicity in this 
model
6
. The dose-dependent amelioration of 
nephrotoxicity in this model by vitamin B-
complex is clinically important. If explored at a 
molecular level, it may elicit additional 
information on the mechanism of gentamicin 
toxicity. Vitamin B-complex is commonly used 
clinical therapy but studies in humans are 
necessary to confirm findings from this work 
before clinical use of the approach used in our 
study is adopted. It is expected to be safer 
than the use of a calcium channel blocker or 
calcium loading. Though complete inhibition of 
gentamicin toxicity at 3ml/kg body weight/day 
was way beyond the preliminary hypothesis 
for this study, amelioration was expected 
because previous studies have shown 
significant amelioration of toxicity by prydoxal-
6-phosphate (B6) and free radical moppers
1
. It 
is interesting to note that the amount of 
vitamin B-complex given to animals in this 
study (1.5 and 3ml of B-complex) translates to 
a pyridoxal-6-phosphate dose range of 1.5  to 
3mg/kg/body weight while previous studies 
have shown pyridoxal-6-phosphate to reduce, 
but not prevent, gentamicin nephrotoxicity at 
doses above 10mg/kg body weight (usually 
100mg/kg body weight)
12,13
. These studies 
also found doses below 10mg/kg to be 
ineffective
12,13
. The efficacy of the much lower 
doses used in this study may suggest 
synergism with some other components of 
vitamin B-complex.  The mechanism of the 
apparent synergism will need to be explored.  
One drawback to this study is that vitamin B-
complex is not a uniform combination 
formulation. Though all formulations usually 
contain B1, B2 and B6, the quantity and ratios 
are often different. Furthermore, some also 
contain nicotinamide and ascorbic acid. These 
may influence the effect on gentamicin 
nephrotoxicity either positively or negatively.  
However, given that these are free radical 
moppers, the expectation is that there could 
be synergism in ameliorating nephrotoxicity.  
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Table 1: Body weight, and serum urea and creatine values of albino rats 
 
Parameter Body Weight (g) Serum Urea (mmol/l) Serum Creatine   (mg/dl) 













































































































All values are mean of 4 values ± standard deviation. 
* Significantly (P<0.05) different from the preceding reading within its group, using t-test, and from all 





















































     Day 0      Day 5      Day 10
 
Figure 1: Amelioration of the increase in serum urea by vitamin B-complex injection.  
 
G1: Control. G2:  Gentamicin 80mg i.m daily for 10 days. G3: gentamicin 80mg  i.m daily for 10 days plus 
B-complex , 1.5ml daily for 10 days. G4: gentamicin 80mg i.m. daily for 10 days plus B-complex , 3ml daily 
for 10days. 
B-Complex:  Vitamin B-complex containing 100mg, 15mg and 10mg of B1, B2 and B6 respectively per 10 
ml ampoule.  
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Figure 2: Amelioration of increase in serum creatine by intramuscular vitamin B-complex 
 
G1: Control. G2:  Gentamicin 80mg i.m daily for 10 days. G3: gentamicin 80mg  i.m daily for 10 days plus 
B-complex , 1.5ml daily for 10 days. G4: gentamicin 80mg i.m. daily for 10 days plus B-complex , 3ml daily 
for 10days; B-Complex:  Vitamin B-complex containing 100mg, 15mg and 10mg of B1, B2 and B6 
respectively per 10 ml ampoule. 
 
The pharmaceutical, pharmacokinetic and 
pharmocodynamic interactions of B-complex 
with gentamicin may also need to be defined. 
The B–complex used in this study and the 
quantity of its components was chosen at 
random. It best serves as a baseline for 




Gentamicin nephrotoxicity may be ameliorated 
or prevented by vitamin B–complex. This 
finding is clinically important but needs to be 
explored further to determine the optimum 
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